AYTU AYTU BIOPHARMA, INC
Pharmaceutical Preparations · Nasdaq · SEC CIK 1385818 · Fiscal year ends 06/30
Financial factors as of 2026-09-30 (2027Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY-8.1%
TTM net income YoY-53.8%
TTM EPS YoY-55.0%
Revenue 3-yr CAGR-15.7%
Net income 3-yr CAGR—
Margins
Gross margin63.3%
Operating margin-18.4%
Net margin-34.3%
FCF margin—
EBITDA margin-14.2%
Returns
ROE-73.4%
ROA-17.9%
ROIC (approx.)-87.4%
Asset turnover0.52x
Leverage & solvency
Liabilities / assets68.2%
Debt / equity0.33x
Current ratio1.07x
Interest coverage-6.01x
Cash quality & payout
Operating cash flow / net income-0.18x
Accruals ratio-21.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2027Q12026-09-30 | 2026Q4*2026-06-30 | 2026Q32026-03-31 | 2026Q22025-12-31 | 2026Q12025-09-30 | 2025Q4*2025-06-30 | 2025Q32025-03-31 | 2025Q22024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $14.84M | $16.11M | $12.41M | $15.16M | $13.89M | $15.13M | $18.45M | $16.22M |
| Cost of revenue | $5.41M | $5.70M | $4.81M | $5.54M | $4.70M | $4.88M | $5.65M | $5.43M |
| Gross profit | $9.44M | $10.41M | $7.60M | $9.62M | $9.19M | $10.25M | $12.81M | $10.79M |
| R&D expense | — | $0 | $0 | $0 | $0 | $216,000 | $162,000 | $522,000 |
| SG&A expense | $5.99M | $4.30M | $4.97M | $5.07M | $4.92M | $3.70M | $4.11M | $4.45M |
| Operating income | -$3.93M | -$777,000 | -$4.06M | -$1.97M | -$1.50M | -$7.62M | $2.42M | -$1.70M |
| Interest expense | $408,000 | $383,000 | $436,000 | $560,000 | $516,000 | $730,000 | $900,000 | $1.08M |
| Pretax income | -$3.88M | -$4,000 | -$5.61M | -$10.58M | $1.97M | -$19.44M | $3.82M | $382,000 |
| Income tax | $0 | $11,000 | $10,000 | $0 | $0 | $437,000 | -$122,000 | -$283,000 |
| Net income | -$3.88M | -$15,000 | -$5.62M | -$10.58M | $1.97M | -$19.82M | $3.99M | $788,000 |
| EBITDA | -$2.81M | $344,000 | -$3.96M | -$1.87M | -$701,000 | -$6.16M | $2.52M | -$1.59M |
| EPS (basic) | -0.20 | — | -0.53 | -1.05 | 0.21 | — | 0.65 | 0.13 |
| EPS (diluted) | -0.20 | — | -0.53 | -1.05 | -0.08 | — | 0.21 | -0.26 |
| Weighted avg. shares (diluted) | 19.33M | — | 10.51M | 10.04M | 19.48M | — | 8.20M | 8.49M |
| Balance sheet | ||||||||
| Cash & equivalents | $25.49M | $26.31M | $26.71M | $30.02M | $32.63M | $30.95M | $18.17M | $20.40M |
| Receivables | $20.33M | $22.78M | $24.49M | $30.92M | $33.23M | $31.16M | $35.83M | $25.40M |
| Inventory | $6.02M | $6.86M | $7.46M | $8.66M | $10.10M | $11.43M | $11.06M | $11.09M |
| Current assets | $57.16M | $61.76M | $67.33M | $76.24M | $81.11M | $79.18M | $72.51M | — |
| PP&E, net | $353,000 | $385,000 | $407,000 | $484,000 | $500,000 | $532,000 | $546,000 | $516,000 |
| Intangibles | $40.32M | $41.40M | $42.49M | $43.58M | $41.43M | $42.20M | $48.71M | $49.96M |
| Total assets | $99.17M | $105.01M | $111.69M | $122.00M | $124.99M | $124.18M | $124.20M | $116.23M |
| Current liabilities | $53.33M | $54.66M | $59.97M | $65.56M | $65.99M | $63.06M | $70.71M | $64.05M |
| Short-term debt | $1.86M | $1.86M | $1.86M | $1.86M | $1.86M | $1.86M | $1.86M | $1.86M |
| Long-term debt | $8.65M | $9.10M | $9.55M | $10.00M | $10.45M | $10.89M | $9.54M | $9.98M |
| Total debt | $10.51M | $10.96M | $11.41M | $11.86M | $12.30M | $12.75M | $11.39M | $11.84M |
| Total liabilities | $67.61M | $69.73M | $76.55M | $107.80M | $101.82M | $105.21M | $89.30M | $85.46M |
| Shareholders' equity | $31.56M | $35.27M | $35.14M | $14.20M | $23.17M | $18.97M | $34.90M | $30.77M |
| Net debt | -$14.98M | -$15.35M | -$15.31M | -$18.17M | -$20.33M | -$18.20M | -$6.78M | -$8.56M |
| Shares outstanding | 10.87M | 10.73M | 10.73M | 10.73M | 9.91M | 8.98M | 6.17M | 6.17M |
| Cash flow statement | ||||||||
| Operating cash flow | -$275,000 | $4.41M | -$4.18M | $3.67M | -$618,000 | $2.80M | -$6.46M | $2.90M |
| Capital expenditure | — | $12,000 | $0 | $17,000 | $0 | $17,000 | $69,000 | $6,000 |
| Free cash flow | — | $4.39M | -$4.18M | $3.66M | -$618,000 | $2.79M | -$6.52M | $2.90M |
| Investing cash flow | — | -$12,000 | $0 | -$17,000 | $0 | -$3.02M | -$69,000 | $145,000 |
| Financing cash flow | -$539,000 | -$4.80M | $872,000 | -$6.26M | $2.30M | $12.99M | $4.30M | -$2.76M |
| Depreciation & amortization | $1.12M | $1.12M | $100,000 | $100,000 | $803,000 | $1.46M | $100,000 | $100,000 |
| Stock-based compensation | $171,000 | $146,000 | $148,000 | $283,000 | $114,000 | $113,000 | $139,000 | $151,000 |
Free plan shows the latest 8 periods; Pro shows all 69 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.